Medical imaging firm Guerbet's 2025 revenue falls on lower sales activity in France

Guerbet SA

11/03/2026 17:02

Overview

France-based medical imaging firm's 2025 revenue fell 3.5% at CER and like-for-like

Company posted €112.7 mln net loss

Guerbet will not pay 2025 dividend; expects significant negative impact in 2026 from Raleigh site issues

Outlook

Company expects significant negative impact in 2026 on revenue, profitability and cash generation

Guerbet warns of probable risk of covenant breach on June 30, 2026

Company expects Raleigh site to return to normal release rate by end of 2026

Result Drivers

FRENCH MARKET CONTRACTION - Revenue decline mainly due to lower activity in France

RALEIGH SITE DISRUPTION - Loss of revenue in Q4 tied to delayed batch releases at Raleigh plant due to FDA compliance work

PRICE PRESSURE IN U.S. - Profitability hurt by price pressure and higher share of distributor sales in U.S. market

Company press release: ID:nGNE2Dgrmc

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
EUR 786.4 mln


Analyst Coverage

The current average analyst rating on the shares is "sell" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Guerbet SA is €13.60, about 8.3% above its March 10 closing price of €12.56

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)